載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.9716
+US$0.0216 · +2.27%
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.
前收盤價
US$0.9716
+US$0.0216 · +2.27%
盤中時間採用ET。市場資料可能有所延遲。
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.
日內區間
目前US$0.9716
52週區間
目前US$0.9716
盤中時間採用ET。市場資料可能有所延遲。
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.
日內區間
目前US$0.9716
52週區間
目前US$0.9716
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 659.11萬 USD | 331.11萬 USD | 351.35萬 USD | 124.17萬 USD |
| 銷貨成本 | — | 1346.78萬 USD | 1041.68萬 USD | 1196.84萬 USD | 316.26萬 USD |
| 毛利 | — | −687.68萬 USD | −710.57萬 USD | −845.49萬 USD | −192.09萬 USD |
| 研究與開發 | 1179.92萬 USD | 1346.78萬 USD | 1041.68萬 USD | 1196.84萬 USD | 2779.49萬 USD |
| 銷售、一般及管理費用 | 418.48萬 USD | 424.16萬 USD | 747.57萬 USD | 1133.61萬 USD | 976.22萬 USD |
| 營業費用 | 1289.04萬 USD | 424.16萬 USD | 747.57萬 USD | 1133.61萬 USD | 3755.71萬 USD |
| 利息收入 | 59.42萬 USD | 43.7萬 USD | 53.92萬 USD | 24.81萬 USD | 5700 USD |
| 折舊和攤銷 | — | 2 USD | 278.91萬 USD | 368.04萬 USD | 316.26萬 USD |
| 營業利益 | −1289.04萬 USD | −1111.84萬 USD | −1458.14萬 USD | −1979.1萬 USD | −3947.8萬 USD |
| 淨利 | −1216.36萬 USD | −1073.13萬 USD | −823.68萬 USD | −2993.07萬 USD | −4187.89萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2023年1月27日 | 1:10 | — | — |
股票分割 | 2016年9月16日 | 1:12 | — | — |
股票分割 | 2014年2月25日 | 1:100 | — | — |
股票分割 | 2009年7月27日 | 1:10 | — | — |
股票分割 | 2008年4月4日 | 2:5 | — | — |
股票分割 | 2007年6月28日 | 2:5 | — | — |
已生效 2023年1月27日
1:10
已生效 2016年9月16日
1:12
已生效 2014年2月25日
1:100
已生效 2009年7月27日
1:10
已生效 2008年4月4日
2:5
已生效 2007年6月28日
2:5
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
